for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Gilead Sciences, Inc.

GILD.O

Latest Trade

76.35USD

Change

0.29(+0.38%)

Volume

6,373,552

Today's Range

75.65

 - 

77.09

52 Week Range

60.89

 - 

85.97

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
76.06
Open
76.31
Volume
6,373,552
3M AVG Volume
359.92
Today's High
77.09
Today's Low
75.65
52 Week High
85.97
52 Week Low
60.89
Shares Out (MIL)
1,254.37
Market Cap (MIL)
95,407.64
Forward P/E
11.80
Dividend (Yield %)
3.58

Next Event

Q2 2020 Gilead Sciences Inc Earnings Release

Latest Developments

More

Gilead does not expect discounts on remdesivir in U.S. commercial market

EMA Recommends First COVID-19 Treatment For EU Authorisation

Gilead Sciences Secures Exclusive Option To Acquire Pionyr Immunotherapeutics

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Gilead Sciences, Inc.

Gilead Sciences, Inc. is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company's portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions. Its products for HIV/AIDS patients include Descovy, Odefsey, Genvoya, Stribild, Complera/Eviplera, Truvada, Emtriva, Tybost and Vitekta. Its products for patients with liver diseases include Vemlidy, Epclusa, Harvoni, Sovaldi, Viread and Hepsera. It offers Zydelig to patients with hematology/oncology diseases. Its products for patients with various cardiovascular diseases include Letairis, Ranexa and Lexiscan. Its products for various inflammation/respiratory diseases include Cayston and Tamiflu. It had operations in more than 30 countries, as of December 31, 2016.

Industry

Biotechnology & Drugs

Contact Info

333 LAKESIDE DR

FOSTER CITY, CA

94404

United States

+1.650.5743000

https://www.gilead.com/

Executive Leadership

Daniel O'Day

Chairman of the Board, Chief Executive Officer

Andrew D. Dickinson

Chief Financial Officer, Executive Vice President

Brett Alan Pletcher

Executive Vice President, Chief Compliance Officer, General Counsel, Corporate Secretary

Jyoti Mehra

Executive Vice President of Human Resources

Linda Higgins

Senior Vice President - Head of External Innovation

Key Stats

2.57 mean rating - 30 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

26.1K

2018

22.1K

2019

22.4K

2020(E)

22.8K
EPS (USD)

2017

8.840

2018

6.670

2019

6.630

2020(E)

6.447
Price To Earnings (TTM)
19.55
Price To Sales (TTM)
4.20
Price To Book (MRQ)
4.32
Price To Cash Flow (TTM)
15.08
Total Debt To Equity (MRQ)
109.20
LT Debt To Equity (MRQ)
100.14
Return on Investment (TTM)
9.48
Return on Equity (TTM)
8.05

Latest News

Latest News

World takes stock of COVID-19 drug remdesivir after U.S. snaps up supplies

Some governments in Europe and Asia said on Wednesday they have enough of Gilead's COVID-19 anti-viral remdesivir for now despite fears of shortages since the U.S. drugmaker pledged most output to its home market for the next three months.

UK emergency remdesivir supplies adequate to treat COVID-19, official says

Britain has adequate supplies of Gilead's remdesivir for emergency use to treat hospitalised COVID-19 patients, England's deputy chief medical officer said on Wednesday, though he warned of potential difficulties securing future supplies.

EU in talks with Gilead to get remdesivir doses for EU countries

The European Commission said on Wednesday it was in negotiations with Gilead Sciences Inc to obtain doses of COVID-19 antiviral remdesivir for the 27 European Union countries.

South Korea to start talks on COVID-19 drug remdesivir purchases in August

South Korea has started distributing stocks of the COVID-19 treatment remdesivir that have been donated by Gilead Sciences Inc and plans to begin talks to purchase more supplies in August, its disease control agency said on Wednesday.

Germany has for now enough remdesivir for COVID-19 therapy: govt

Germany has secured enough supplies for now of remdesivir, which is set to become the first COVID-19 treatment approved in Europe, and is banking on developer Gilead to meet future needs, the country's health ministry said on Wednesday.

BRIEF-Gilead Sciences Shows Commitment To Scientific Innovation In HIV With New Prevention, Treatment & Cure Research Data

* GILEAD SCIENCES DEMONSTRATES COMMITMENT TO SCIENTIFIC INNOVATION IN HIV WITH NEW PREVENTION, TREATMENT AND CURE RESEARCH DATA PRESENTED AT AIDS 2020: VIRTUAL

South Korea begins supply of Gilead's remdesivir -KCDC

South Korea started supplying Gilead's antiviral drug for the treatment of the novel coronavirus on Wednesday, the Korea Centers for Disease Control and Prevention (KCDC) said.

BRIEF-Humanigen - First Patient Infused In Zuma-19 Study, Being Conducted In Collaboration With Kite

* HUMANIGEN INC - FIRST PATIENT INFUSED IN ZUMA-19 STUDY, BEING CONDUCTED IN COLLABORATION WITH KITE, A GILEAD COMPANY Source text for Eikon: Further company coverage:

Breakingviews - Gilead gives glimpse into feverish drug market

Medicine may be a science but drug pricing is definitely an art. That’s especially true of Gilead Sciences’ treatment for Covid-19, given the lack of alternative treatments for a pandemic. The $2,300 price of a course of remdesivir may sound high – and is compared with the...

Gilead prices COVID-19 drug remdesivir at $2,340 per patient in developed nations

Gilead Sciences Inc <GILD.O> on Monday priced its COVID-19 antiviral remdesivir at $2,340 per patient for wealthier nations and agreed to send nearly all of its supply of the drug to the United States over the next three months.

BRIEF-Gilead does not expect discounts on remdesivir in U.S. commercial market

* Says does not expect additional discounts on $520 per vial price for remdesivir in the commercial market in U.S. Further company coverage: (Reporting By Michael Erman)

UPDATE 1-Gilead prices COVID-19 drug candidate remdesivir at $2,340 per patient in U.S.

Gilead Sciences Inc has priced its COVID-19 drug candidate remdesivir at $390 per vial for the United States and governments of other developed countries, it said on Monday, setting the price of a five-day course at $2,340 per patient.

Gilead prices COVID-19 drug candidate remdesivir at $390/vial in U.S.

Gilead Sciences Inc said on Monday it has priced its COVID-19 treatment candidate remdesivir at $390 per vial in the United States and other developed countries.

BRIEF-Gilead Terminates License Agreement For Long-Acting Injectable HIV Investigational Product

* GILEAD TERMINATES LICENSE AGREEMENT FOR LONG-ACTING INJECTABLE HIV INVESTIGATIONAL PRODUCT

South Korea backs remdesivir for COVID-19, urges caution with dexamethasone

South Korea has added Gilead's anti-viral drug remdesivir to its coronavirus treatment guidelines in its first revision of recommendations since the outbreak began and urged caution in the use of the steroid therapy dexamethasone.

U.S. to ship remdesivir to states including California and Texas with rising COVID-19 cases

The U.S. government will ship more of Gilead Sciences Inc's <GILD.O> antiviral treatment remdesivir to states experiencing an increase in COVID-19 cases including California, Texas, Florida and Arizona, according to the Department of Health and Human Services' website.

Gilead's remdesivir set to become Europe's first COVID-19 therapy

Doctors in Europe will soon be able to treat COVID-19 patients with Gilead's antiviral drug, remdesivir, after the healthcare regulator's endorsement put it on track to become the first therapy for the disease on the continent.

EU drug regulator endorses Gilead's remdesivir as COVID-19 treatment

June 25 - The European healthcare regulator said on Thursday it had recommended conditionally approving Gilead Sciences Inc's antiviral treatment, remdesivir, for use in COVID-19 patients across the continent, just weeks after a speedy review.

U.S. group raises pricing recommendation for Gilead's remdesivir in COVID-19

Gilead Sciences Inc's antiviral remdesivir could be priced up to $5,080 per course based on benefits shown in COVID-19 patients, a U.S. drug pricing research group suggested on Wednesday, above its prior recommendation of around $4,500.

FACTBOX-Price estimates for Gilead's remdesivir for COVID-19

The potential U.S. pricing of Gilead Sciences Inc's antiviral remdesivir, among the first drugs shown to be effective against COVID-19, has been a highly debated topic among investors and analysts. What Gilead could charge for remdesivir after its pledged donations are used...

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up